Pharmacological effects of non-steroidal antiinflammatory agents on prostaglandin and leukotriene synthesis in mouse peritoneal macrophages

• Published in: Biochemical pharmacology Vol. 32; no. 15; p. 2319
• Main Authors: Humes, J L, Sadowski, S, Galavage, M, Goldenberg, M, Subers, E, Kuehl, Jr, F A, Bonney, R J
• Format: Journal Article
• Language: English
• Published: England 01-08-1983
• Subjects: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; Animals; Anti-Inflammatory Agents - pharmacology; Ascitic Fluid - cytology; Aspirin - pharmacology; Female; Guinea Pigs; Ibuprofen - pharmacology; Indomethacin - pharmacology; Macrophages - drug effects; Macrophages - metabolism; Male; Mice; Propionates - pharmacology; Prostaglandins - biosynthesis; Pyrazoles - pharmacology; SRS-A - biosynthesis; Zymosan - pharmacology
• ISSN: 0006-2952
• DOI: 10.1016/0006-2952(83)90179-x

Resident mouse peritoneal macrophages, exposed to zymosan, synthesized and released products of both the cyclooxygenase and lipoxygenase pathways. The effects of various non-steroidal antiinflammatory agents were evaluated for their abilities to inhibit zymosan-stimulated prostaglandin E2 (PGE2) and leukotriene C4 (LTC4) synthesis. The order of potencies to inhibit PGE2 synthesis and release was: indomethacin greater than or equal to sulindac sulfide greater than ibuprofen greater than or equal to aspirin greater than 3-amino-1-[3-(trifluoromethyl)-phenyl]-2-pyrazoline (BW755C) greater than benoxaprofen greater than or equal to nordihydroguaiaretic acid (NDGA) greater than 5,8,11-eicosatriynoic acid (ETYA). BW755C and ETYA also inhibited zymosan-stimulated LTC4 production. None of the compounds tested showed selective inhibition of lipoxygenase products.